We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Lactation Study in Women Who Are Breastfeeding or Pumping and Are Receiving Linaclotide Therapeutically (LIN-PK-01)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02220348
Recruitment Status : Recruiting
First Posted : August 19, 2014
Last Update Posted : December 22, 2017
Information provided by (Responsible Party):
Forest Laboratories

Brief Summary:
The purpose of this study is to determine the amount of linaclotide and its active metabolite (MM-419447) excreted in breast milk after multiple, once daily doses of linaclotide (145 μg or 290 μg) in lactating women receiving the drug therapeutically.

Condition or disease Intervention/treatment Phase
Breast Feeding Constipation Irritable Bowel Syndrome Drug: linaclotide Phase 1

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 8 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: An Open-label, Multiple-dose, Milk-only Lactation Study in Lactating Women Receiving Linaclotide Therapeutically
Study Start Date : July 2014
Estimated Primary Completion Date : May 31, 2018
Estimated Study Completion Date : May 31, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breastfeeding
U.S. FDA Resources

Arm Intervention/treatment
Experimental: linaclotide
Linaclotide 145 μg or 290 μg capsules, once daily for 3 days, oral administration
Drug: linaclotide
Other Name: Linzess

Primary Outcome Measures :
  1. Amount of linaclotide and its active metabolite (MM-419447) excreted in breast milk [ Time Frame: From Baseline (Day 1) to Day 4 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Be a lactating female who has been actively breastfeeding or pumping for at least 4 weeks
  • Be already taking linaclotide therapeutically for Irritable Bowel Syndrome with Constipation (IBS-C) or Chronic Idiopathic Constipation (CIC)
  • Weaning must not be underway
  • Be willing to breastfeed or pump regularly during the study to maintain milk supply and discontinue breastfeeding for the 24-hour period of breast milk collection

Exclusion Criteria:

  • Clinically significant disease state in any body system, except for the indication being treated with linaclotide
  • Any structural abnormality of the gastrointestinal (GI) tract, or a disease or condition that can affect GI motility
  • Participation in any other clinical investigation using an experimental drug within 90 days

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02220348

Contact: Clinical Trials Registry Team 877‐277‐8566 IR-CTRegistration@allergan.com

United States, Iowa
University of Iowa Recruiting
Iowa City, Iowa, United States, 52242
United States, Pennsylvania
Forest Investigative Site 002 Withdrawn
Philadelphia, Pennsylvania, United States, 19140
Sponsors and Collaborators
Forest Laboratories
Study Director: Ramesh Boinpally, PhD Forest Research Institute, an affiliate of Allergan plc.

Responsible Party: Forest Laboratories
ClinicalTrials.gov Identifier: NCT02220348     History of Changes
Other Study ID Numbers: LIN-PK-01
First Posted: August 19, 2014    Key Record Dates
Last Update Posted: December 22, 2017
Last Verified: December 2017

Keywords provided by Forest Laboratories:

Additional relevant MeSH terms:
Irritable Bowel Syndrome
Signs and Symptoms, Digestive
Signs and Symptoms
Colonic Diseases, Functional
Colonic Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases